Why do investors like Hande Capital look at this company? What is the attraction of Hubei Renfu Medicine? Hande Capital said that the acquisition was mainly based on two reasons. One is that the company has the leading BFS (Blow-Fill-Seal, Blow-Fill-Seal) production technology in the United States; second, the technology is in the Chinese market. Can land, and is expected to have a wider range of needs in the future.
Hande Capital, which specializes in investing in European technology, has invested in the US market for the first time in two years. On June 26, Hande Capital announced that its leading international consortium has signed an agreement with private equity fund Olympus Partners to acquire a stake in the US medical technology company The Ritedose Corporation.
Caixin reporter was informed that the amount of the acquisition was 605 million US dollars. The buyer consortium consists of four parties, in addition to the leader Hande, including CIC, an American asset management company and Hubei Renfu Medicine. Piper Jaffray & Co. Exclusive merger and debt financing advisor for this transaction. Gibson, Dunn & Crutcher LLP and Jones Day acted as legal counsel for the acquisition of the consortium.
The head of Hande Capital said that the investment project began to be viewed about half a year ago. The acquisition was mainly based on two reasons. First, the company has the US leading BFS (Blow-Fill-Seal, blow-fill-seal) Production technology; Second, the technology can be implemented in the Chinese market, and it is expected that there will be more demand in the future.
Riedose, Inc. was founded in 1995 in South Carolina, USA, and is the number one manufacturer of single-dose sterile pharmaceuticals using BFS technology in the United States. BFS technology allows the plastic container to be blown, filled with liquid and packaged under aseptic conditions. In the injectable drug market, BFS technology is gradually replacing the glass bottle processing method and is considered by the US Food and Drug Administration (FDA) as an excellent method for aseptic drug filling. In addition to BFS technology, Ritedose is also engaged in the production of sterile pharmaceuticals for the treatment of respiratory and ophthalmic diseases.
Sun Zheng, managing director and head of Greater China, believes that respiratory medicines and BFS technology will generate more demand in the future in China and Japan. "Now there is a lot of fog in China. In the future, many respiratory diseases may need to use this technology." The head of the above-mentioned Hande Capital said.
BFS technology is currently in the early stage of development in China. Compared with foreign technology, there are still gaps in quality and safety. The Ministry of Industry and Information Technology has proposed to encourage the introduction and absorption of advanced BFS technology in the “Twelfth Five-Year Plan†and the “Thirteenth Five-Year Planâ€. Hande Capital said that this acquisition is to fill a gap in the country's important medical technology. Hubei Renfu Medicine in the buyer consortium will be the parent of the project, and establish a production enterprise in Hubei to introduce and put into production technology.
Feed Grade Vitamins,Vitamin K Powder,Natural Vitamin E,Bulk Vitamin B Powder
Ningbo Nutrition Food Technology Co.,ltd. , https://www.collagenworkshop.com